WSJ
23 Jul 2026, 10:48 UTC · 2h ago
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
WSJ
23 Jul 2026, 10:48 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide. — Progress toward regulatory filing for a high-demand obesity drug suggests a clear path to commercialization and significant revenue growth.
+0.80Two Phase 3 trials for retatrutide showed the treatment delivered substantial results. — Positive Phase 3 data significantly reduces clinical risk and increases the probability of FDA approval.
+0.60Which stocks this story touches
Positive Phase 3 trial data for retatrutide supports the preparation of application materials for a next-generation weight-loss drug.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
2h ago
